Outcome MeasureDepression

BPRS (Anxiety/Depression)

Brief Psychiatric Rating Scale – Anxious-Depression Subscale

2 Papers in Blossom

Clinical Thresholds

Minimal symptoms

Mild

Moderate

Severe

428

Minimal symptoms

Score 4–8

Mild

Score 9–14

Moderate

Score 15–21

Severe

Score 22–28

Outcome Data Across Studies

Reported results for BPRS (Anxiety/Depression) across 2 studies with quantitative data.

Outcome data across 7 study arm–timepoint observations
					SD
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report 2015Secondary	Ayahuasca(experimental)	0	6	—	—	—
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report 2015Secondary	Ayahuasca(experimental)	1	6	—Δ	—	—
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report 2015Secondary	Ayahuasca(experimental)	7	6	—Δ	—	—
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report 2015Secondary	Ayahuasca(experimental)	14	6	—Δ	—	—
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report 2015Secondary	Ayahuasca(experimental)	21	6	—Δ	—	—
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial 2018Safety	Ayahuasca(experimental)	0	14	—	—	—
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial 2018Safety	Placebo(inactive)	0	15	—	—	—

Papers Using BPRS (Anxiety/Depression)

Open Accessindividual

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

In a double-blind randomised placebo-controlled trial of 29 patients with treatment-resistant depression, a single dose of ayahuasca produced rapid antidepressant effects versus placebo at days 1, 2 and 7, with effect sizes increasing from Cohen’s d = 0.84 to 1.49 and higher response rates at day 7 (64% v. 27%). This first controlled trial of a psychedelic in this population supports the safety and therapeutic potential of ayahuasca when dosed in an appropriate setting.

Published: June 15, 2018
Journal: Psychological Medicine
Authors: Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., De Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., Hallak, J. E. C., Arcoverde, E., Maia-De-Oliveira, J. P., Araújo, D. B.

Open Accessindividual

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

This open-label study (n=6) found that a single dose of ayahuasca has fast-acting anxiolytic and antidepressant effects (up to 21 days later, MADRS) in patients with a current depressive episode.

Published: March 1, 2015
Journal: brazilian Journal of Psychiatry
Authors: Crippa, J. A., de Araujo, D. B., Dos Santos, R. G., Hallak, J. E., Macedo, L., Maia-de-Oliveira, J. P., Osório, F. L., Riba, J., Sanches, R. F., Wichert-Ana, L.

Quick Facts

Full Name: Brief Psychiatric Rating Scale – Anxious-Depression Subscale
Domain: Depression
Papers Indexed: 2
Score Range: 4–28
Interpretation: Lower = better
Unit: points

All Measures